Related by context. All words. (Click for frequent words.) 85 Phase IIa clinical 83 Phase 2b clinical 82 Phase 2a 82 phase IIa clinical 81 Phase IIb clinical 81 Phase IIa 80 Phase 2a trial 80 Phase 2b study 80 Phase IIa trial 79 Phase Ib clinical 79 Phase 1b clinical 79 phase IIb clinical 79 Phase III clinical 78 Phase 2b trial 78 phase IIa 78 Phase Ib 77 pivotal Phase III 77 phase IIb 77 Phase 1a clinical 77 phase 2a 77 Phase IIb trial 76 Phase 1b 76 Phase IIb 75 Phase 1b trial 75 dose escalation Phase 75 Phase 2b 74 Phase IIIb clinical 74 Phase III 74 pivotal Phase 74 Phase Ia 74 Phase Ib study 74 multicenter Phase 74 dose escalation trial 73 Phase 1a 73 Phase IIb trials 73 phase Ib 73 multiple ascending dose 73 Phase 2b clinical trials 73 dose escalation clinical 72 phase IIb study 72 confirmatory Phase III 72 placebo controlled Phase 72 phase IIb trial 72 Phase Ib II 72 placebo controlled clinical 72 randomized Phase IIb 72 APEX PD 72 pharmacokinetic PK study 72 multicenter Phase II 71 Phase #b/#a clinical 71 Phase IIB 71 Phase III pivotal 71 alvespimycin 71 Phase II 71 pharmacokinetic PK 71 phase Ib clinical 71 confirmatory Phase 3 71 randomized Phase III 70 PRX # 70 clinical trial 70 dose escalation study 70 Phase IIIb 70 ADVANCE PD 70 randomized Phase 70 placebo controlled Phase III 70 multicenter clinical 70 Phase Ib clinical trials 70 randomized controlled Phase 69 IIa clinical trial 69 Phase III clinical trials 69 MEND CABG 69 INCB# [001] 69 BRIM2 69 PDX pralatrexate 69 forodesine 69 Phase III ALLEGRO 69 Phase #b/#a 69 Phase IIa trials 69 BRIM3 69 oral ridaforolimus 69 registrational trial 69 rALLy clinical trial 69 IIa trial 69 NGX# 69 Initiated Phase 69 evaluating tivozanib 68 placebo controlled 68 single ascending dose 68 trial evaluating PRX# 68 oral prodrug 68 SUCCEED trial 68 phase IIIb 68 SPIRIT FIRST 68 ongoing Phase 1b 68 R#/MEM # 68 fosbretabulin 68 JAK inhibitor 68 KRN# 68 Phase Ib IIa 68 pharmacokinetics PK 68 Traficet EN 68 lomitapide 68 European Sepsis Trial 68 Phase 1b clinical trials 68 Phase #/#a 68 multicenter randomized placebo controlled 68 Phase IIb clinical trials 68 Randomized Phase 68 multicenter Phase III 68 CB2 selective receptor agonist 67 elotuzumab 67 Phase IIb III 67 investigational compound 67 FOLOTYN ® 67 investigational pan BCR 67 TG MV 67 opioid induced bowel dysfunction 67 Zenvia ™ 67 cannabinor 67 RSD# oral 67 Phase 2b randomized 67 TMC# C# 67 IMA# 67 brivaracetam 67 pivotal bioequivalence 67 phase IIb III 67 relapsed refractory multiple myeloma 67 randomized Phase 2b 67 II Clinical Trial 67 CRx 67 Nasdaq NYMX 67 randomized multicenter 67 randomized placebo controlled 67 EDEMA3 67 viral kinetic 67 investigational drug 67 ELACYT 66 CRLX# 66 davunetide intranasal AL 66 QLT# 66 initiate Phase IIb 66 huC# DM4 66 refractory gout 66 AEG# 66 Phase III placebo controlled 66 Androxal TM 66 double blind placebo 66 Zenvia Phase III 66 multicenter phase 66 virus HCV protease inhibitor 66 MERLIN TIMI 66 MAP# 66 PHX# 66 PEG PAL 66 Ophena TM 66 PS# DARA 66 Amrubicin 66 Phase 1b dose escalation 66 double blinded placebo 66 Fx #A 66 CEQ# 66 Phase 2a clinical trials 66 Cloretazine R VNP#M 66 preclinical efficacy 66 Oral NKTR 66 investigational humanized monoclonal antibody 66 Phase 2b monotherapy 66 Locteron ® 66 GALNS 66 double blinded randomized 66 Phase #b/#a trial 66 Cloretazine ® 66 registrational 66 teriflunomide 66 CR# vcMMAE 66 MEND CABG II 66 PRE SURGE 66 PFO migraine 66 tanespimycin 66 TASKi2 66 PRECiSE 66 dirucotide 66 NP2 Enkephalin 66 Phase III trials 65 bicifadine 65 lintuzumab SGN 65 Phase III randomized 65 NO# [002] 65 randomized controlled multicenter 65 ISIS # 65 EOquin TM 65 Sym# 65 Phase III Pivotal 65 Investigational Device Exemption IDE 65 PSN# [002] 65 Archexin 65 axitinib 65 Phenoptin 65 ZYBRESTAT fosbretabulin 65 vidofludimus 65 diabetic neuropathic pain 65 Phase IIa clinical trials 65 selective androgen receptor modulator 65 LymphoStat B TM 65 novel histone deacetylase 65 PANVAC VF 65 Plicera 65 label dose escalation 65 alvimopan 65 HGS# 65 Pivotal Phase III 65 RDEA# 65 blinded randomized placebo controlled 65 Initiate Phase 65 histone deacetylase HDAC inhibitor 65 elacytarabine 65 anticancer compound 65 Phase 65 prospective multicenter randomized 65 midstage trials 65 randomized controlled clinical 65 Phase 2b kidney transplant 65 ZYBRESTAT 65 preclinical studies 65 huN# DM1 65 neurogenic orthostatic hypotension 65 Elagolix 65 GetGoal Phase III 65 IIb clinical trial 65 trastuzumab DM1 T DM1 65 dextofisopam 65 EDEMA4 65 treatment naive genotype 65 ENDEAVOR III 65 ABSORB trial 65 APPRAISE 65 Alzhemed TM 65 IMPACT IMmunotherapy 64 pseudobulbar affect PBA 64 fostamatinib 64 cell lymphoma CTCL 64 deforolimus 64 fidaxomicin Phase 3 64 Phase IIb Trial 64 non nucleoside inhibitor 64 Safinamide 64 PRTX 64 Azedra 64 dose cohort 64 oral rivaroxaban 64 lorvotuzumab mertansine 64 ruxolitinib 64 Nasdaq MAPP 64 PS# [001] 64 multicenter randomized Phase 64 placebo controlled randomized 64 compound INCB# 64 PDE4 inhibitor 64 dyskinesia PD LID 64 lintuzumab 64 AQ4N 64 GAMMAGARD 64 Quinamed 64 Tesetaxel 64 Denufosol 64 AEGR 64 prospective multicenter 64 TBC# 64 multicenter randomized controlled 64 ORMD 64 AIR CF1 64 Phase III randomized controlled 64 Bicifadine 64 EVEREST II 64 XL# XL# XL# 64 initiated Phase Ib 64 LUX Lung 64 REG2 64 evaluating REVLIMID 64 Phase IIA 64 Phase III confirmatory 64 LibiGel Phase III 64 Phase III VISTA 64 ACTEMRA TM 64 ADAGIO study 64 Genasense ® oblimersen 64 MEK inhibitor RDEA# 64 relapsed multiple myeloma 64 NASDAQ CXSP announced 64 preclinical 64 mGluR5 negative 64 Microplasmin 64 randomized controlled 64 HGS ETR1 64 TRO# 64 liposomal formulation 64 riociguat 64 multicenter placebo controlled 64 multicenter randomized 64 Azedra TM 64 glufosfamide 64 humanized anti 64 multicenter prospective 64 HCV SPRINT 64 assessing T DM1 64 ENDEAVOR IV 64 treatment naïve genotype 64 clinical pharmacology studies 64 multicentre randomized 64 masked placebo controlled 64 ALN TTR# 64 ILUVIEN ® 64 sNDA submission 64 HCV RESPOND 2 64 initiate Phase 1b 64 confirmatory clinical 64 Fibrillex TM 64 pharmacokinetic studies 64 investigational oral 64 prospective randomized controlled 64 Phase IIIb study 64 SCH # 64 CIMZIA TM certolizumab pegol 64 BCX# 64 Ozarelix 64 TLK# 64 torezolid phosphate 64 JZP 64 satraplatin Phase 64 IL# PE#QQR 63 Phase III Clinical Trial 63 unique alkylating agent 63 Phase IIb kidney transplant 63 MAGE A3 ASCI 63 PNP inhibitor 63 multicenter 63 Curaxin CBLC# 63 phase III ACCLAIM 63 Phase III ADT 63 Mipomersen 63 dexanabinol 63 ToGA 63 Triolex 63 enzastaurin 63 candidate XP# 63 CRMD# 63 Pivotal Phase 63 Pimavanserin 63 blinded placebo controlled 63 JAK2 inhibitor 63 Phase III Trial 63 MIST II 63 elagolix 63 Troxatyl 63 RE SURGE 63 docetaxel Taxotere R 63 metastatic hormone refractory 63 crizotinib PF # 63 label multicenter 63 CHAMPION PCI 63 telomerase inhibitor drug 63 ganetespib 63 OMNARIS HFA 63 Anturol TM 63 radiation sensitizer 63 velafermin 63 OncoVEX GM CSF 63 HCV NS5B polymerase 63 orally inhaled migraine 63 mertansine 63 ProSavin 63 nucleotide analog 63 ATL# [001] 63 LEVADEX 63 PXD# 63 Dacogen injection 63 BAY #-# 63 safety tolerability 63 Phase 2b Clinical Trial 63 Spiegelmer ® 63 trodusquemine 63 RG# [001] 63 Phase #/#a clinical 63 EOquin 63 Daclizumab 63 tolerability 63 GLYX 63 multicenter randomized double 63 initiate Phase 63 Laquinimod 63 AZILECT R 63 Aurexis 63 trastuzumab emtansine T DM1 63 visilizumab 63 inhaled formulation 63 hypoxia activated prodrug 63 tezampanel 63 alemtuzumab Campath 63 CCR5 antagonist 63 Augment Injectable 63 denufosol 63 lead Aganocide compound 63 blind randomized placebo 63 CA4P 63 Tanespimycin 63 orally bioavailable 63 Phase #/#a trial 63 EGS# 63 sulodexide 63 Inc. Nasdaq VVUS 63 rNAPc2 63 DDP# 63 EDEMA3 trial 63 HGS ETR2 63 ANCHOR trial 63 randomized clinical 63 diarrhea predominant irritable 63 sorafenib Nexavar 63 PROVENGE sipuleucel T 63 Inhalation Solution 63 pharmacokinetic 63 CALGB # [002] 63 HCV protease inhibitor 63 Dapagliflozin 63 XL# SAR# 63 HuMax EGFr 63 LEVADEX ™ 63 dose dose escalation 63 Bezielle 63 HuMax CD4 63 COU AA 63 eculizumab 63 OHR/AVR# 63 IRX 2 63 Aflibercept 63 ulimorelin 63 ORENCIA ® 63 Intervention Effectiveness 63 Parkinson disease levodopa induced 63 LE SN# 63 Phase III psoriasis 63 tiapamil 63 ABSORB clinical 63 pertuzumab 63 oral deforolimus 63 pharmacodynamic PD 63 Prostate AdenoCarcinoma Treatment 63 Cannabinor 63 randomized double 63 INCB# [002] 62 OvaRex ® MAb 62 NASDAQ NYMX 62 LibiGel ® 62 teduglutide 62 IIa clinical 62 Sorafenib HCC Assessment 62 dextromethorphan quinidine 62 acyclovir Lauriad R 62 desvenlafaxine succinate 62 Corlux 62 Zybrestat 62 mitogen activated ERK kinase 62 metaglidasen 62 investigational protease inhibitor 62 COMFORT II 62 CCX# B 62 initiate Phase 2b 62 metastatic castration resistant 62 EXPAREL ™ 62 MEK inhibitor 62 MLN# 62 Alocrest 62 Veronate 62 octreotide implant 62 Phase IIb Clinical Trial 62 Pharmacokinetics PK 62 LymphoStat B 62 next generation URAT1 62 TG# [003] 62 DASISION 62 Factor VIIa 62 PRT# 62 AP# [003] 62 mGluR5 NAM 62 PERSEUS 62 Serdaxin ® 62 AACR NCI EORTC 62 PD LID 62 TELINTRA 62 rALLy trial 62 #th Annual Interscience 62 lucinactant 62 varespladib 62 Carfilzomib 62 HQK 62 Ocrelizumab 62 Tarvacin TM 62 Enzastaurin 62 Panzem R 62 Phase 2a proof 62 LUNESTA TM 62 sunitinib malate 62 Tyrima 62 dose escalation 62 Cleviprex TM clevidipine 62 HCD# [002] 62 TACI Ig 62 Aclidinium 62 metastatic HRPC 62 dosing cohorts 62 controlled multicenter 62 Onalta ™ 62 apricitabine ATC 62 Omacetaxine 62 LUMINATE 62 neratinib 62 RSD# 62 Zerenex 62 VNP#M 62 6R BH4 62 antibody MAb 62 relapsing remitting multiple sclerosis 62 Serada 62 Pivotal Trial 62 AIR CF2 62 Phase III multicenter 62 VA# [002] 62 CUSTOM III 62 RGB # 62 candidate CRLX# 62 Atiprimod 62 Meets Primary Endpoint 62 clinical trials 62 NVA# 62 TELCYTA 62 IMPACT DCM 62 Hsp# Inhibitor 62 incyclinide 62 ATL/TV# 62 vascular disrupting agent 62 lexidronam injection 62 oral formulation 62 Genz # 62 Nasdaq RDEA 62 mGluR2 positive 62 Zenvia TM 62 sodium Injection 62 NASDAQ ARRY 62 Combination REOLYSIN R 62 IND submission 62 ACTEMRA 62 perifosine KRX 62 Diabetic Macular Edema DME 62 omacetaxine mepesuccinate 62 Tarceva TM 62 TEMSO 62 INSPIRE Trial Phase III 62 VICTOR E1 62 DermaVir Patch 62 Completes Patient Enrollment 62 Ambrisentan 62 PROPEL trial 62 Phase 2a Clinical Trial 62 drug pipeline TAFA# 62 Ceflatonin R 62 PSMA ADC 62 LibiGel testosterone gel 62 generation purine nucleoside 62 ocular formulation 62 Ostarine 62 budesonide foam 62 severe gastroparesis 62 dependent kinase inhibitor 62 cariprazine 62 SinuNase TM 62 targeted radiotherapeutic 62 recurrent glioblastoma multiforme 62 interferon gamma 1b 62 STRIDE PD 62 RhuDex ® 62 eltrombopag 62 TRANSFORMS 62 TPI ASM8 62 PRECISE trial 62 MIVI III 62 novel VDA molecule 62 prucalopride 62 ThermoDox R 62 randomized multicenter Phase III 62 TAXUS ATLAS 62 registrational Phase 62 novel oral anticoagulant 62 PI3K/Akt pathway inhibitor 62 preclinical pharmacokinetic 62 Proxinium TM 62 Annamycin 62 alagebrium 62 GOUT 62 Urocortin 2 62 Azixa 62 CTAP# Capsules 62 EXPAREL TM 62 Cloretazine 62 EchoCRT 62 vosaroxin 62 TMC# [002] 62 PLK1 SNALP 62 ELND# 62 PRIMO CABG 62 efficacy endpoint 62 PEGylated Fab fragment 62 LEP ETU 61 ILLUMINATE 61 thorough QT 61 Initiates Phase II 61 GLP toxicology studies 61 catheter occlusion 61 RE COVER 61 dasatinib Sprycel ® 61 transcriptase inhibitor NNRTI 61 GEM OS2 61 ExTRACT TIMI 61 BOLDER II 61 cathepsin K inhibitor 61 ApoB SNALP 61 dosing cohort 61 generation PNP inhibitor 61 Darusentan 61 Phase 2b Trial 61 ofatumumab HuMax CD# 61 Cimzia TM 61 allosteric modulator NAM 61 leading oral taxane 61 postoperative ileus POI 61 Genasense ® 61 tolevamer 61 evaluating Actimmune 61 Capesaris 61 systemic RNAi therapeutic 61 Cethrin R 61 reslizumab 61 multicentre randomized double 61 ASCO abstract 61 Nasdaq PGNX today 61 Cimzia ® certolizumab pegol 61 Solazed TM 61 nonclinical studies 61 IPL# 61 Dyloject TM 61 obatoclax 61 TOCOSOL Paclitaxel 61 aclidinium bromide 61 Nasdaq DVAX 61 refractory chronic lymphocytic 61 Atu# 61 Phase III metastatic melanoma 61 ospemifene 61 prospective randomized placebo 61 Chemophase 61 Silodosin 61 Exherin TM 61 LCP Tacro 61 controlled multicenter Phase 61 Phase III HEAT 61 ZFP Therapeutic 61 ZYBRESTAT TM 61 methylnaltrexone 61 candidate Zenvia 61 Clinical Antipsychotic Trials 61 EVIZON 61 Degarelix 61 prospective observational 61 MBP# [001] 61 CIMZIA ™ 61 Allovectin 7 61 Phase IIB clinical 61 REVLIMID lenalidomide 61 lumiliximab 61 INCB# [003] 61 midstage clinical 61 microplasmin 61 Dextofisopam 61 cancer neuroendocrine tumor 61 TASKi3 61 AZX# 61 Xanafide 61 Vicriviroc 61 AMD# [002] 61 MOZOBIL 61 entinostat 61 Endovascular Valve Edge 61 Hyphanox 61 label multicenter Phase 61 Tolvaptan 61 CIMZIA TM 61 Empatic 61 ALN TTR 61 ancrod 61 investigational hepatitis C 61 BR.# 61 relapsing multiple sclerosis 61 CLARITY study 61 tolerability profile 61 Aryplase 61 FOLFOX6 chemotherapy regimen 61 YONDELIS 61 GSK# [002] 61 dose cohorts 61 blinded randomized 61 ARDIS 61 Study Evaluating 61 ADX# 61 EmbraceAC 61 GLPG# 61 NLX P# 61 PEG SN# 61 CBLC# 61 Diabetic Macular Edema 61 IMGN# 61 DB# [003] 61 REVIVE Diabetes 61 Zemiva ™ 61 CCX# 61 EXPLORE Xa 61 ZOLINZA 61 inhaled liposomal ciprofloxacin 61 mapatumumab 61 CYT# 61 TRX1 61 AeroLEF TM 61 GEM OS1 61 APEX AMI trial 61 nalbuphine ER 61 tasimelteon 61 Excellarate TM 61 ASSERT trial 61 Nasdaq VRTX 61 Phase III Clinical Trials 61 albiglutide 61 randomized discontinuation trial 61 depsipeptide 61 NYSE Amex PTN 61 active comparator 61 Asentar 61 unblinding 61 AIR2 Trial 61 ALN VSP Phase 61 CLIRS trial 61 Hedgehog pathway inhibitor 61 LymphoStat B belimumab 61 PreCISe 61 histamine dihydrochloride 61 prospective randomized 61 ANAVEX #-# [003] 61 SYMMETRY trial 61 Omigard 61 MINDSET 61 pharmacodynamics 61 3 registrational trial 61 ORAL Sync 61 Myocet 61 pralatrexate injection 61 pharmacodynamic profile 61 ® natalizumab 61 PrevOnco 61 RELOVAIR ™ 61 Zoraxel 61 rilonacept 61 Hsp# inhibitor 61 Serdaxin 61 polymerase inhibitor 61 seliciclib CYC# 61 initiate Phase IIa 61 rasagiline tablets 61 investigational antiplatelet agent 61 bortezomib Velcade 61 subcutaneous formulation 61 telaprevir VX 61 CRD5 61 TH# [003] 61 randomized blinded 61 Personalized Immunotherapy 61 IMC #B 61 Tezampanel 61 arzoxifene 61 IDX# 61 Testosterone MDTS ® 61 Ophena 61 Memryte 61 darusentan 61 clinicaltrials 61 INT# [002] 61 dimebon 61 Iluvien ® 61 IIa clinical trials 61 bevirimat Study 61 talactoferrin 61 Ixempra 61 miconazole Lauriad ® 61 severe hypercholesterolemia 61 refractory cutaneous T 61 Oral Fingolimod 61 ACAPODENE 61 tafamidis 61 Phase Ib Clinical Trial 61 BrachySil TM 60 Phase lll 60 ThGRF 60 sodium thiosulfate STS 60 lorcaserin Phase 60 dacetuzumab SGN 60 systemic anaplastic large 60 oral methylnaltrexone 60 Anturol ® 60 laquinimod 60 prospective randomized multicenter 60 L Annamycin 60 PROVENGE ® 60 Hedgehog Pathway Inhibitor 60 intranasal formulation 60 Guanilib 60 dacetuzumab 60 refractory AML 60 ZACTIMA 60 NOX E# 60 OncoGel 60 tramiprosate Alzhemed TM 60 labial herpes 60 custirsen 60 QNEXA 60 TOLAMBA 60 platinum refractory 60 ozarelix 60 AAG geldanamycin analog 60 IIa trials 60 PEG Interferon lambda 60 rALLy 60 ostarine 60 tezampanel NGX# 60 PRX# 60 unblinded 60 aldehyde dehydrogenase ALDH2 deficiency 60 #nd EORTC NCI 60 R#/MEM 60 Prosaptide 60 pomalidomide 60 celgosivir 60 safety tolerability pharmacokinetics 60 ponatinib 60 ularitide 60 ANG# 60 Nuvion 60 sitaxsentan 60 REVEAL Registry 60 dirucotide MBP# 60 cangrelor 60 ONCONASE R 60 LCP AtorFen 60 EFAPROXYN 60 Clinical Trial Results 60 PRNewswire FirstCall Genta Incorporated 60 OXi# 60 aclidinium 60 OPT CHF 60 COSIRA trial 60 initiated Phase 1b 60 cediranib 60 recurrent malignant glioma 60 XL# [003] 60 VELCADE melphalan 60 MGCD# [001] 60 Kamada AAT 60 receptor tyrosine kinase inhibitor 60 TKB# 60 SILENOR TM 60 Tasimelteon 60 AA Amyloidosis 60 Aeroquin 60 Randomized Double blind 60 IMC A# 60 Genasense R oblimersen 60 generation Hsp# inhibitor 60 ANYARA 60 ENDEAVOR II 60 amrubicin 60 recurrent glioma 60 AGILECT ® 60 vaginally administered lidocaine 60 BETAS 60 AEZS 60 Arikace 60 PrevOnco ™ 60 PF # [002] 60 randomized multicenter trial 60 R roscovitine CDK cyclin 60 CCR9 antagonist 60 SPRYCEL ® 60 immunotherapeutic agent 60 NCCTG 60 AVADO 60 BLA filing 60 synthetic retinoid 60 RRMS patients 60 inhibitor RG# 60 Genasense oblimersen sodium Injection 60 subcutaneously administered 60 CTA# Injection 60 Lu AA# 60 R PEG uricase 60 Triapine 60 SPIRIT III 60 OMNARIS Nasal Spray 60 CYT# potent vascular disrupting 60 ascending dose 60 EVIZON TM 60 immunosuppressive compound 60 GATTEX ™ 60 Matrix Phase 2b 60 demonstrated antitumor activity 60 Edge STudy 60 OvaRex R 60 MYDICAR ® 60 FTY# fingolimod 60 Phase IIa proof 60 Achieves Primary Endpoint 60 cutaneous T cell 60 personalized cellular immunotherapy 60 cetrorelix 60 bazedoxifene conjugated estrogens 60 Virulizin ® 60 Aurora kinase inhibitor 60 Sapacitabine 60 cystinosis patients 60 carfilzomib 60 NASDAQ CYTK announced 60 label multicenter randomized 60 nitazoxanide 60 HspE7 60 TSX ONY 60 peripherally acting 60 Elocalcitol 60 drug eluting coronary stent 60 NasdaqGM NTEC today 60 castration resistant prostate cancer 60 MGd 60 Entereg TM 60 mGluR2 NAM 60 PARTNER Trial 60 Cloretazine R 60 Plecanatide 60 eosinophilic asthma 60 IMPACT DCM clinical 60 GRN# 60 Dr. Fahar Merchant 60 oxymorphone ER 60 zanolimumab 60 JAK1 60 Prodarsan ® 60 orally administered inhibitor 60 Multiple Ascending Dose 60 topical formulation 60 SPIRIT IV 60 Trofex 60 comparing alemtuzumab 60 Nasdaq PPHM 60 virus HCV infection 60 Raptiva ® 60 GRN#L 60 sorafenib tablets 60 Nasdaq HALO 60 VESTASYNC 60 candidate AQ4N 60 Advaxis Phase 60 ORACLE MS 60 Menerba 60 mg/m2 cohort 60 Onrigin 60 BLOOM Behavioral modification 60 PROTECT AF 60 MDV# 60 Unit Dose Budesonide 60 stated Michelle Berrey 60 RLY# 60 Gabapentin GR 60 ThermoDox ® 60 iniparib 60 transthyretin TTR mediated amyloidosis 60 VITAL Trial 60 Cytokinetics Incorporated NASDAQ CYTK 60 fallopian tube cancers 60 multi kinase inhibitor 60 acetonide FA 60 R roscovitine 60 generation NNRTI 60 Luveniq 60 sodium glucose cotransporter 60 RoACTEMRA 60 Lodotra TM 60 Sunovion